



**DEPARTMENT OF COMMERCE  
Foreign-Trade Zones Board  
[B-37-2022]**

**Foreign-Trade Zone (FTZ) 35 – Philadelphia, Pennsylvania, Notification of Proposed Production Activity, Piramal Pharma Solutions (Pharmaceutical Products), Sellersville, Pennsylvania**

Piramal Pharma Solutions submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Sellersville, Pennsylvania under FTZ 35. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on August 19, 2022.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website – accessible via [www.trade.gov/ftz](http://www.trade.gov/ftz).

The proposed finished products are bempedoic acid and ezetimibe tablets (180/10 milligrams) (duty-free).

The proposed foreign-status materials are bempedoic acid and ezetimibe (duty rate ranges from 4% to 6.5%). The request indicates that the materials are subject to duties under Section 301 of the Trade Act of 1974 (section 301), depending on the country of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: [ftz@trade.gov](mailto:ftz@trade.gov). The closing period for their receipt is **[INSERT DATE 40 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]**.

A copy of the notification will be available for public inspection in the "Online FTZ Information System" section of the Board's website.

For further information, contact Christopher Wedderburn at  
Chris.Wedderburn@trade.gov.

Dated: August 23, 2022.

**Andrew McGilvray,**  
*Executive Secretary.*

[FR Doc. 2022-18470 Filed: 8/25/2022 8:45 am; Publication Date: 8/26/2022]